• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CAISMOV24,一种新型人低级别浆液性卵巢癌细胞系。

CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.

机构信息

Faculdade de Ciências Médicas, University of Campinas, Campinas, SP, Brazil.

Instituto de Biologia, University of Campinas, Campinas, SP, Brazil.

出版信息

BMC Cancer. 2017 Nov 13;17(1):756. doi: 10.1186/s12885-017-3716-4.

DOI:10.1186/s12885-017-3716-4
PMID:29132324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5683553/
Abstract

BACKGROUND

The spontaneous immortalization of primary malignant cells is frequently assigned to their genetic instability during in vitro culturing. In this study, the new epithelial ovarian cancer cell line CAISMOV24 was described and compared with its original low-grade serous ovarian carcinoma.

METHODS

The in vitro culture was established with cells isolated from ascites of a 60-year-old female patient with recurrent ovarian cancer. The CAISMOV24 line was assessed for cell growth, production of soluble biomarkers, expression of surface molecules and screened for typical mutations found in serous ovarian carcinoma. Additionally, comparative genomic hybridization was employed to compare genomic alterations between the CAISMOV24 cell line and its primary malignant cells.

RESULTS

CAISMOV24 has been in continuous culture for more than 30 months and more than 100 in vitro passages. The cell surface molecules EpCAM, PVR and CD73 are overexpressed on CAISMOV24 cells compared to the primary malignant cells. CAISMOV24 continues to produce CA125 and HE4 in vitro. Although the cell line had developed alongside the accumulation of genomic alterations (28 CNV in primary cells and 37 CNV in CAISMOV24), most of them were related to CNVs already present in primary malignant cells. CAISMOV24 cell line harbored KRAS mutation with wild type TP53, therefore it is characterized as low-grade serous carcinoma.

CONCLUSION

Our results corroborate with the idea that genomic alterations, depicted by CNVs, can be used for subtyping epithelial ovarian carcinomas. Additionally, CAISMOV24 cell line was characterized as a low-grade serous ovarian carcinoma, which still resembles its primary malignant cells.

摘要

背景

原发性恶性细胞的自发永生化通常归因于其在体外培养过程中的遗传不稳定性。本研究描述了一种新的卵巢上皮癌细胞系 CAISMOV24,并将其与原始的低级别浆液性卵巢癌进行了比较。

方法

从一名 60 岁女性复发性卵巢癌患者的腹水分离细胞,建立体外培养。评估 CAISMOV24 系的细胞生长、可溶性生物标志物的产生、表面分子的表达,并筛选出浆液性卵巢癌中常见的突变。此外,还采用比较基因组杂交技术比较 CAISMOV24 细胞系与其原始恶性细胞的基因组改变。

结果

CAISMOV24 已连续培养超过 30 个月和 100 多次体外传代。与原始恶性细胞相比,CAISMOV24 细胞表面分子 EpCAM、PVR 和 CD73 过表达。CAISMOV24 继续在体外产生 CA125 和 HE4。尽管该细胞系伴随着基因组改变的积累(原发性细胞中有 28 个 CNV,CAISMOV24 中有 37 个 CNV),但大多数改变与原发性恶性细胞中已经存在的 CNV 相关。CAISMOV24 细胞系存在 KRAS 突变和野生型 TP53,因此其特征为低级别浆液性癌。

结论

我们的结果证实了基因组改变(由 CNV 描述)可用于上皮性卵巢癌的亚分型。此外,CAISMOV24 细胞系被鉴定为低级别浆液性卵巢癌,其仍与原始恶性细胞相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/46d627d1ab62/12885_2017_3716_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/e31722343434/12885_2017_3716_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/e1aa5ccf0986/12885_2017_3716_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/a61af34e69ef/12885_2017_3716_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/763042d1a42a/12885_2017_3716_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/46d627d1ab62/12885_2017_3716_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/e31722343434/12885_2017_3716_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/e1aa5ccf0986/12885_2017_3716_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/a61af34e69ef/12885_2017_3716_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/763042d1a42a/12885_2017_3716_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589e/5683553/46d627d1ab62/12885_2017_3716_Fig5_HTML.jpg

相似文献

1
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.CAISMOV24,一种新型人低级别浆液性卵巢癌细胞系。
BMC Cancer. 2017 Nov 13;17(1):756. doi: 10.1186/s12885-017-3716-4.
2
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.具有交界性分化的浆液性卵巢癌的基因组分类可区分 RAS 通路和 TP53 突变型肿瘤,并确定 NRAS 为致癌驱动基因。
Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14.
3
Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.新型高级别浆液性卵巢癌细胞系 OVPA8 的建立与鉴定。
Int J Mol Sci. 2018 Jul 17;19(7):2080. doi: 10.3390/ijms19072080.
4
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.卵巢浆液性癌中活性丝裂原活化蛋白激酶的特征分析
Clin Cancer Res. 2004 Oct 1;10(19):6432-6. doi: 10.1158/1078-0432.CCR-04-0893.
5
Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.同期发生的卵巢浆液性交界性肿瘤和随后发生的浆液性癌的临床病理和分子特征。
Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325.
6
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.中国患者高级别浆液性卵巢癌的全面基因组分析鉴定出 Ras/Raf 通路与 TP53 共发生的突变。
Cancer Med. 2019 Jul;8(8):3928-3935. doi: 10.1002/cam4.2243. Epub 2019 May 24.
7
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.卵巢癌细胞释放的微颗粒进入腹水并促进细胞迁移。
Int J Gynecol Cancer. 2012 May;22(4):546-52. doi: 10.1097/IGC.0b013e318241d9b9.
8
Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.Eph 受体 A1 表达降低与卵巢浆液性癌分级有关。
Mol Med Rep. 2018 Apr;17(4):5409-5415. doi: 10.3892/mmr.2018.8528. Epub 2018 Jan 31.
9
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.卵巢浆液性交界性肿瘤中 KRAS(而非 BRAF)突变与复发性低级别浆液性癌相关。
J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.
10
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.低级别浆液性卵巢癌:从分子特征到最佳治疗策略。
Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23.

引用本文的文献

1
Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.罕见的上皮性卵巢癌:低级别浆液性和黏液性癌。
Cold Spring Harb Perspect Med. 2023 Sep 1;13(9):a038190. doi: 10.1101/cshperspect.a038190.
2
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.患者来源的肿瘤模型是重新利用药物治疗卵巢癌的有吸引力的工具:临床前更新。
Oncotarget. 2022 Mar 24;13:553-575. doi: 10.18632/oncotarget.28220. eCollection 2022.
3
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.

本文引用的文献

1
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.分子特征明确的低级别浆液性卵巢癌细胞系中MEK抑制剂疗效的差异
Am J Cancer Res. 2016 Oct 1;6(10):2235-2251. eCollection 2016.
2
Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.惰性、侵袭性及复发性卵巢低级别浆液性癌的分子改变
Histopathology. 2017 Feb;70(3):347-358. doi: 10.1111/his.13071. Epub 2016 Nov 7.
3
Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer.
卵巢癌相关腹水富含细胞因子反应性 CD56brightNK 细胞。
Cells. 2021 Jul 6;10(7):1702. doi: 10.3390/cells10071702.
4
Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.建立并鉴定来源于低级别浆液性卵巢癌腹膜转移的细胞系和患者来源的异种移植瘤(PDX)。
Sci Rep. 2020 Apr 21;10(1):6688. doi: 10.1038/s41598-020-63738-6.
5
Three-Dimensional Cell Culture Based on Magnetic Fields to Assemble Low-Grade Ovarian Carcinoma Cell Aggregates Containing Lymphocytes.基于磁场的三维细胞培养方法来组装含有淋巴细胞的低级别卵巢癌细胞聚集体。
Cells. 2020 Mar 6;9(3):635. doi: 10.3390/cells9030635.
卵巢癌中复发性局灶性拷贝数变异及其假定的靶向驱动基因的鉴定。
BMC Bioinformatics. 2016 May 26;17(1):222. doi: 10.1186/s12859-016-1085-7.
4
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.低级别浆液性卵巢肿瘤的分子图谱分析鉴定出新型候选驱动基因。
Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.
5
HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer.HLA Ⅰ类作为临床预后的预测因子,CTL 浸润作为卵巢癌化疗敏感性的预测因子。
Oncoimmunology. 2015 Mar 23;4(5):e1005507. doi: 10.1080/2162402X.2015.1005507. eCollection 2015 May.
6
Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.使用二代测序技术研究上皮性卵巢癌的肿瘤进化和肿瘤内异质性。
BMC Cancer. 2015 Feb 26;15:85. doi: 10.1186/s12885-015-1077-4.
7
Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer.Notch1表达增加与卵巢癌患者较差的总生存期相关。
Int J Gynecol Cancer. 2015 Feb;25(2):208-13. doi: 10.1097/IGC.0000000000000359.
8
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.低级别浆液性卵巢癌:从分子特征到最佳治疗策略。
Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23.
9
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
10
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.具有交界性分化的浆液性卵巢癌的基因组分类可区分 RAS 通路和 TP53 突变型肿瘤,并确定 NRAS 为致癌驱动基因。
Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14.